Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03342716
Other study ID # v11 23 Sept 2019
Secondary ID MR/P008887/1
Status Completed
Phase
First received
Last updated
Start date November 27, 2017
Est. completion date February 16, 2022

Study information

Verified date February 2022
Source University of Edinburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Acute pancreatitis (AP) is inflammation of the pancreas usually triggered by gallstones or drinking excessive alcohol. 80% of people who have an episode of AP will recover without complications. However, 20% will require treatment in high dependency or intensive care for multiple organ dysfunction (AP-MODS). It is known that this negatively affects recovery and can have a lasting effect on health although it is incompletely understood what causes this. Aim: To recruit 500 patients with acute pancreatitis. Participants will be assessed at recruitment and and again at 3 and 36 months. Recovery of organ function will be serially measured and the presence of novel factors important in recovery assessed.


Description:

Acute pancreatitis (AP) is a common and devastating disease with an annual incidence of 22-30 per 100,000 in the UK. The incidence is increasing. AP is most commonly triggered by gallstones or alcohol excess and has a range of outcomes, from complete resolution to death, with an overall mortality in Scotland of 5.2%. AP is characterised by acute inflammation of the pancreas, which initiates a cascade of inflammatory events throughout the body that can lead to multiple organ dysfunction syndrome (MODS) in approximately 25% of AP patients. Mortality in AP is greatest in those patients who develop MODS, with death rates reported to be up to 28%. The development of persistent organ failure characterises severe AP (SAP) as defined in the revised Atlanta classification, and is strongly predictive of a fatal outcome. A significant proportion of research has focussed on reducing mortality and morbidity in the first week. As a consequence, it remains to be seen whether the patterns of early organ dysfunction are reflected in the causes of long-term mortality and morbidity. Recently published data from a retrospective analysis of patients admitted to the Royal Infirmary of Edinburgh with acute pancreatitis has shown that the early development of MODS is associated with an increased mortality rate up to 10 years after the index presentation. This strongly suggests that MODS in acute pancreatitis (AP-MODS) has a persistent and deleterious impact on patients' physiological status, though the exact nature of this pathology remains to be characterised. Recent data has indicated that the severity of the first attack of AP significantly influences the risk of progression to chronic pancreatitis, and therefore subsequent long-term morbidity. This observational clinical cohort study aims to characterise the nature and extent of the pathophysiological impact of SAP on organ function over the first 3 years following the index event and the long-term deleterious effect of SAP. This will be achieved by prospectively evaluating the pathophysiological consequences of an episode of AP by measuring organ system function in patients recruited during a hospital admission with AP. We will obtain an in-depth assessment of patients' health at presentation, and at 3 months and 36 months after the first episode of AP using markers of organ function and/or disease in the peripheral blood. In a nested cohort within the main study cohort, we will conduct cardiorespiratory evaluation tests (including exercise testing), specialised blood tests of the immune system, tests for precision medicine, and imaging to assess structure and function of key organ systems. The results of this study will inform the design of future interventions designed to improve the long-term prognosis of patients.


Recruitment information / eligibility

Status Completed
Enrollment 229
Est. completion date February 16, 2022
Est. primary completion date January 31, 2022
Accepts healthy volunteers No
Gender All
Age group 16 Years and older
Eligibility Inclusion Criteria: All patients treated at Royal Infirmary Edinburgh with a clinical or radiological diagnosis of acute pancreatitis will be recruited where possible. For the potential clinical diagnosis of acute pancreatitis an appropriate clinical history based on compatible clinical features, will be required (i.e. abdominal pain, nausea and/or vomiting), supported by the finding of elevated serum amylase greater than 3x the upper limit of the reference range for the laboratory (currently 300 U/L). For the radiological diagnosis, if applicable, computerised tomography (CT) and/or ultrasound scan (USS) evidence of acute pancreatitis will be accepted. Exclusion Criteria: The following exclusion criteria will be adhered to: i. Patients under the age of 16 years will be excluded from the present study. ii. Prisoners will be excluded from the present study. iii. Patients lacking the capacity to consent will be excluded but can be included if they regain capacity. Additional exclusions will apply only to those patients being considered for the nested cohort study: iv. Patients not able to undergo MRI scanning for technical reasons will be excluded (e.g. those with cochlear implants, implanted pacemaker) v. Patients with a known allergy to salbutamol

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Royal Infirmary of Edinburgh Edinburgh

Sponsors (2)

Lead Sponsor Collaborator
University of Edinburgh Medical Research Council

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Annual incidence of new-onset type 3c diabetes mellitis in patients with AP Do patients that have had AP develop type 3c diabetes mellitis more frequently? 66 months
Primary Nested cohort only - difference in the 3 month to 36 month change in pancreatic fibrosis index between participants with AP with MODS and those with AP without MODS Assess any damage to pancreas at 3 and 36 months and monitor how this changes throughout the course of the trial comparing participants with AP only and those with AP and MODS 66 months
Secondary Specific gene and promoter sequence variation between participants with AP and AP-MODS Define any gene and promoter sequence variation between participants with AP and AP-MODS; machine learning approach 66 months
Secondary miRNA signatures of disease severity and resolution Comparing patterns of gene expression in mild/moderate/severe cases of AP; machine learning approach 66 months
Secondary Metabolomic profiling of AP resolution. Comparing patterns of metabolite expression in mild/moderate/severe cases of AP; machine learning approach 66 months
Secondary Incidence of premature cellular senescence as a pathological consequence of AP-MODS. Investigating pathological consequences of AP-MODS compared to AP without MODS 66 months
Secondary Alteration in immune cell subset phenotype as a long-term response to AP-MODS Investigating changes to the phenotype of immune cell subsets following an episode of AP; descriptive statistics 66 months
Secondary Cardiorespiratory dysfunction as a legacy of endothelial injury during AP-MODS Determination of cardiorespiratory function following AP using physiological measures including cardiopulmonary exercise testing to determine anaerobic threshold. Descriptive measures. 66 months
See also
  Status Clinical Trial Phase
Recruiting NCT03609944 - SpHincterotomy for Acute Recurrent Pancreatitis N/A
Recruiting NCT05572788 - Rectal Indomethacin to Prevent Acute Pancreatitis in EUS-FNA of Pancreatic Cysts N/A
Completed NCT03642769 - Lactated Ringer's Versus Normal Saline for Acute Pancreatitis N/A
Active, not recruiting NCT05095831 - EUS Shear Wave for Solid Pancreatic Lesions.
Completed NCT04570852 - Acute Pancreatitis Targets (APT) Study N/A
Recruiting NCT03686618 - Secretin for Acute Pancreatitis Phase 2
Not yet recruiting NCT03740685 - Changes in High Sensitive C Reactive Protien With Different Treatment Modalities in Acute Pancreatitis
Not yet recruiting NCT04037449 - Transversus Abdominis Plane Block in the Analgesia of Acute Pancreatitis N/A
Not yet recruiting NCT03342807 - Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis Phase 4
Terminated NCT02959112 - Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography N/A
Recruiting NCT05381428 - Prophylaxis of Post-ERCP Acute Pancreatitis Phase 3
Active, not recruiting NCT05955235 - A Long-term Safety Follow-up Study of SCM-AGH in Patients Who Completed SCM-APT2001 Study
Recruiting NCT05160506 - Corticosteroids to Treat Pancreatitis Phase 2
Not yet recruiting NCT03082469 - Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal Phase 4
Completed NCT03672422 - Pediatric Longitudinal Cohort Study of Chronic Pancreatitis
Completed NCT00490386 - Helicobacter Pylori and Acute Alcohol Induced Pancreatitis N/A
Completed NCT04188990 - Cost Effectiveness of an Intervention in Hospitalized Patients With Disease-related Malnutrition N/A
Active, not recruiting NCT04743323 - A Case-CrossovEr Study deSign to Inform Tailored Interventions to Prevent Disease Progression in Acute Pancreatitis
Completed NCT03829085 - Study of the Diet in Patients With the Diagnostic of Acute Pancreatitis N/A
Not yet recruiting NCT04760847 - Intermittent Fasting for Pancreatitis N/A

External Links